跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 901 条关于
“InflaRx N.V.”
全部
901
临床试验
418
药物
152
机构
181
资讯
150
去年
InflaRx Announces First Patient Dosed in Phase 2a Study for CSU and HS
2年前
InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial
10个月前
InflaRx to Report Phase 2a Results for Oral C5aR Inhibitor INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
10个月前
InflaRx Stock Surges 67.5% Ahead of Critical Phase 2a Trial Results for INF904
3年前
FDA Grants Emergency Use Authorization for Vilobelimab in Treating Critically Ill COVID-19 Patients
去年
InflaRx's Vilobelimab Receives Positive CHMP Opinion for SARS-CoV-2-Induced ARDS
去年
InflaRx's Vilobelimab Receives Positive CHMP Opinion for COVID-19-Induced ARDS
去年
InflaRx's Gohibic (vilobelimab) Receives European Commission Approval for SARS-CoV-2-Induced ARDS
去年
InflaRx Advances Pipeline with Vilobelimab and INF904, Anticipates Key Milestones in 2025
去年
InflaRx's Vilobelimab Receives Positive CHMP Opinion for COVID-19-Induced ARDS
第 1 页,共 15 页
上一页
下一页